Mp60-09 Trends in the Use of Second-Generation Androgen Receptor Axis Inhibitors for Metastatic Hormone-Sensitive Prostate Cancer and Clinical Factors Predicting Biological Recurrence

You have accessJournal of UrologyProstate Cancer: Advanced (Including Drug Therapy) III (MP60)1 May 2024MP60-09 TRENDS IN THE USE OF SECOND-GENERATION ANDROGEN RECEPTOR AXIS INHIBITORS FOR METASTATIC HORMONE-SENSITIVE PROSTATE CANCER AND CLINICAL FACTORS PREDICTING BIOLOGICAL RECURRENCE Keita Nakane, Hiromitsu Watanabe, Taku Naiki, Nagoya Jordan, Kiyoshi Takahara, Takahiro Yasui, Hideaki Miyake, Ryoichi Shiroki, and Takuya Koie Keita NakaneKeita Nakane , Hiromitsu WatanabeHiromitsu Watanabe , Taku NaikiTaku Naiki , Nagoya JordanNagoya Jordan , Kiyoshi TakaharaKiyoshi Takahara , Takahiro YasuiTakahiro Yasui , Hideaki MiyakeHideaki Miyake , Ryoichi ShirokiRyoichi Shiroki , and Takuya KoieTakuya Koie View All Author Informationhttps://doi.org/10.1097/01.JU.0001008804.84010.ec.09AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: It is unclear how treatment methods have changed in real-world practice since 2020 when ARATs became available for use in patients with mHSPC in Japan. In addition, research regarding factors that predict treatment efficacy is lacking. Therefore, we designed a multicenter retrospective study to evaluate patient characteristics and oncologic outcomes as well as to examine clinical factors that predict BRFS. METHODS: Biochemical recurrence-free survival (BRFS) was used to compare the efficacy of each ARAT. This multicenter retrospective study included 581 patients with newly diagnosed mHSPC who received first-line hormone therapy. The characteristics of patients treated with different ARATs were compared as well as changes in the usage of each drug over time. For BRFS, the apalutamide (Apa) and enzalutamide (Enza) groups, as well as the abiraterone acetate (Abi) and Apa/Enza groups, were compared. In addition, multivariate analysis was performed to determine predictive factors for biochemical recurrence (BCR). RESULTS: The use of second-generation ARATs tended to increase after May 2020. No significant difference in BRFS was found between patients receiving Apa and Enza (p=0.490) and those receiving Abi or Apa/Enza (p=0.906). Multivariate analysis revealed that the neutrophil-to-lymphocyte ratio (NLR) ≥2.76 and PSA ≥0.550 ng/mL were independent predictors of BCR. There were no significant differences in patient characteristics or BRFS in patients with mHSPC receiving different ARATs as first-line treatment. CONCLUSIONS: NLR and PSA may be prognostic factors following the first-line treatment of patients with mHSPC. Download PPTDownload PPTDownload PPT Source of Funding: No funding was received for conducting this study © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e1002 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Keita Nakane More articles by this author Hiromitsu Watanabe More articles by this author Taku Naiki More articles by this author Nagoya Jordan More articles by this author Kiyoshi Takahara More articles by this author Takahiro Yasui More articles by this author Hideaki Miyake More articles by this author Ryoichi Shiroki More articles by this author Takuya Koie More articles by this author Expand All Advertisement PDF downloadLoading ...